2025
FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression
Gliniak C, Gordillo R, Youm Y, Lin Q, Crewe C, Zhang Z, Field B, Fujikawa T, Virostek M, Zhao S, Zhu Y, Rosen C, Horvath T, Dixit V, Scherer P. FGF21 promotes longevity in diet-induced obesity through metabolic benefits independent of growth suppression. Cell Metabolism 2025, 37: 1547-1567.e6. PMID: 40527315, DOI: 10.1016/j.cmet.2025.05.011.Peer-Reviewed Original ResearchInflammatory immune cellsVisceral adipose tissueDiet-induced obesityAged transgenic miceHigh-fat dietAbsence of adiponectinTreat metabolic syndromeFibroblast growth factor 21Immune cellsLipotoxic ceramidesMetabolic syndromeReduced liver steatosisTransgenic miceMetabolic profileMetabolic benefitsInsulin sensitivityLiver steatosisIn adulthoodAdipose tissueMiceFat tissueImprove metabolismGrowth suppressionMetabolic issuesAge-related diseasesElevation of hepatic de novo lipogenesis in mice with overnutrition is dependent on multiple substrates
Strober J, Siebel S, Murray S, Rodríguez M, Rodriguez-Navas Gonzalez C, Vatner D. Elevation of hepatic de novo lipogenesis in mice with overnutrition is dependent on multiple substrates. Journal Of Lipid Research 2025, 66: 100838. PMID: 40499904, DOI: 10.1016/j.jlr.2025.100838.Peer-Reviewed Original ResearchCarbon entryAntisense oligonucleotidesIncreased hepatic TG contentGlutamic-pyruvic transaminase 2Amino acidsChronic overnutritionDevelopment of novel therapiesDecreased hepatic triglyceride contentTCA cycle metabolitesInsulin-resistant subjectsIncreased de novo lipogenesisMultiple amino acidsAntisense oligonucleotide treatmentPrevention of dyslipidemiaHepatic triglyceride contentOverfed miceTG contentHepatic de novo lipogenesisHepatic TG contentC57BL6/J miceLactate dehydrogenase ANovel therapiesMultiple substratesMetabolic syndromeCarbon sourceTrends in Prevalence, Treatment, and Relationship of Metabolic Syndrome and Individual Components by Race/Ethnicity, 1999-2018
Lu Y, Li X, Liu Y, Caraballo C, Massey D, Mahajan S, Spatz E, Herrin J, Krumholz H. Trends in Prevalence, Treatment, and Relationship of Metabolic Syndrome and Individual Components by Race/Ethnicity, 1999-2018. JACC Advances 2025, 4: 101785. PMID: 40373521, PMCID: PMC12144450, DOI: 10.1016/j.jacadv.2025.101785.Peer-Reviewed Original ResearchLipid-lowering medication useRacial/ethnic disparitiesMedication useMetS prevalenceRacial/ethnic differencesHispanic individualsAge-standardized prevalence estimatesNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyBlack individualsPersistent racial/ethnic disparitiesFasting glucoseNutrition Examination SurveyRelationship of metabolic syndromeMetabolic syndromePrescription drug useNationally representative dataExamination SurveyMetS componentsWaist circumferenceEligible individualsTreatment gapRacial/ethnic subgroupsU.S. adultsPrevalence estimates16 Metabolic Syndrome and Obesity
Alonso W, Canapari C. 16 Metabolic Syndrome and Obesity. 2025, 175-184. DOI: 10.1016/b978-0-323-75566-5.00016-2.Peer-Reviewed Original ResearchMetabolic syndromeComponents of metabolic syndromeInvolvement of adipocytokinesSleep-disordered breathingIncreased sympathetic activityElevated blood pressureCardiovascular risk factorsRates of obesityIntermittent hypoxemiaTruncal obesityDysregulation of glucose metabolismSleep fragmentationSympathetic activityBlood pressureSleep curtailmentRisk factorsSyndromeObesityShort sleepGlucose metabolismCircadian factorsSleepHypoxemiaDyslipidemiaAdipocytokines
2024
Afamin Ameliorates Testosterone Propionate (TP)-Induced Oxidative Stress and Mitochondrial Damage in Human Ovarian Granulosa Tumor Cells (KGN) by Upregulating the Expression of SIRT1
Ma Y, Li Z, Wang Z, Yang A. Afamin Ameliorates Testosterone Propionate (TP)-Induced Oxidative Stress and Mitochondrial Damage in Human Ovarian Granulosa Tumor Cells (KGN) by Upregulating the Expression of SIRT1. Molecular Biology 2024, 58: 1250-1267. DOI: 10.1134/s0026893324060074.Peer-Reviewed Original ResearchPCOS micePolycystic ovary syndromeGranulosa tumor cellsLuteinizing hormoneTumor cellsKGN cellsTestosterone propionateDevelopment of metabolic syndromeOxidative stressWomen of reproductive ageLevels of afaminExpression of SIRT1Reactive oxygen speciesLH/follicle-stimulating hormonePolycystic ovary syndrome patientsEndocrine disorder affecting women of reproductive ageMitochondrial damageLevels of 8-hydroxydeoxyguanosineEndocrine disorder affecting womenTreatment of polycystic ovary syndromeMetabolic syndromeReproductive ageCystic folliclesEstrous cycleTP-induced oxidative stressAssociation of uric acid and fructose levels in polycystic ovary syndrome
Feng D, Wang X, Song J, Yang H, Peng Y, Wang X, Chen W, Li P, Fang Y, Shi B, Li D. Association of uric acid and fructose levels in polycystic ovary syndrome. Human Reproduction 2024, 39: 2575-2586. PMID: 39380170, DOI: 10.1093/humrep/deae219.Peer-Reviewed Original ResearchPolycystic ovary syndromeSerum uric acidUric acid levelsSerum fructose levelsSerum uric acid levelsIndependent risk factorDiagnosis of polycystic ovary syndromeClinical diagnosis of polycystic ovary syndromeMetabolic disordersGranulosa cellsReal-time PCRControl womenShengjing HospitalMetabolic syndromeUric acidElevated serum uric acid levelsQuantitative real-time PCRRisk factorsAssociation of uric acidShengjing Hospital of China Medical UniversityAcid levelsInsulin resistanceIncreased risk of anovulationFructose metabolismHospital of China Medical UniversityGLP-1 programs the neurovascular landscape
Chen B, Yu X, Horvath-Diano C, Ortuño M, Tschöp M, Jastreboff A, Schneeberger M. GLP-1 programs the neurovascular landscape. Cell Metabolism 2024, 36: 2173-2189. PMID: 39357509, DOI: 10.1016/j.cmet.2024.09.003.Peer-Reviewed Original ResearchConceptsGLP-1R agonismGLP-1RMetabolic healthChronic low-grade inflammationLow-grade inflammationGlucagon-like peptide-1 receptorPersistent health issuesCognitive well-beingNutrient-rich foodsPeptide-1 receptorMetabolic syndromeHealth issuesMetabolic defectsBrain healthMetabolic environmentObesityWell-beingWeight lossHealthMetabolic conditionsAgonismNeurological conditionsAnalysis of drug–drug interactions in patients with HIV and metabolic syndrome
Tuan J, Igiraneza G, Ogbuagu O. Analysis of drug–drug interactions in patients with HIV and metabolic syndrome. Expert Opinion On Drug Metabolism & Toxicology 2024, 20: 953-965. PMID: 39230187, DOI: 10.1080/17425255.2024.2401044.Peer-Reviewed Original ResearchDrug-drug interactionsAntiretroviral therapyMetabolic disordersMetabolic syndromeNanotechnology-based drug delivery platformsPrevalence of metabolic comorbiditiesSelection of antiretroviral therapyLong-acting antiretroviral therapyContemporary antiretroviral therapyEffective antiretroviral therapyPrevalence of metabolic disordersRepertoire of treatment optionsDrug-drug interaction dataTreat metabolic syndromeMetabolic comorbiditiesTreatment optionsDrug delivery platformPrescribing informationAnalysis of drug-drug interactionsHIVInjectable medicationsDrug prescribing informationWeight lossPWHSyndromeAldehydes alter TGF-β signaling and induce obesity and cancer
Yang X, Bhowmick K, Rao S, Xiang X, Ohshiro K, Amdur R, Hassan M, Mohammad T, Crandall K, Cifani P, Shetty K, Lyons S, Merrill J, Vegesna A, John S, Latham P, Crawford J, Mishra B, Dasarathy S, Wang X, Yu H, Wang Z, Huang H, Krainer A, Mishra L. Aldehydes alter TGF-β signaling and induce obesity and cancer. Cell Reports 2024, 43: 114676. PMID: 39217614, PMCID: PMC11560041, DOI: 10.1016/j.celrep.2024.114676.Peer-Reviewed Original ResearchAldehyde dehydrogenase 2Small interfering RNADisease progression to cancerPro-oncogenic phenotypeTGF-bProgression to cancerGrowth factor BTGF-b signalingHuman metabolic syndromeSteatotic liver diseasePotential therapeutic targetMetabolic syndromePro-fibroticInduce obesityTherapeutic inhibitionLiver diseaseCurrent treatmentSmad3 signalingGlucose handlingTherapeutic targetFunctional phenotypeDehydrogenase 2Improve glucose handlingSPTBN1ObesityRetraction notice to “A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design” [Mech. Ageing Dev. 213 (2023) 111825]
Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev O, Azuri Y, Carmichael O, Kapogiannis D, Zetterberg H, Lin H, Sano M, Beeri M. Retraction notice to “A feasibility study of the combination of intranasal insulin with dulaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design” [Mech. Ageing Dev. 213 (2023) 111825]. Mechanisms Of Ageing And Development 2024, 219: 111937. PMID: 38702256, PMCID: PMC12124240, DOI: 10.1016/j.mad.2024.111937.Peer-Reviewed Original ResearchRecurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
Berardi G, Cucchetti A, Sposito C, Ratti F, Nebbia M, D’Souza D, Pascual F, Dogeas E, Tohme S, Vitale A, D’Amico F, Alessandris R, Panetta V, Simonelli I, Colasanti M, Russolillo N, Moro A, Fiorentini G, Serenari M, Rotellar F, Zimitti G, Famularo S, Ivanics T, Donando F, Hoffman D, Onkendi E, Essaji Y, Giuliani T, Ben S, Caula C, Rompianesi G, Chopra A, Abu Hilal M, Sapisochin G, Torzilli G, Corvera C, Alseidi A, Helton S, Troisi R, Simo K, Conrad C, Cescon M, Cleary S, Kwon D, Ferrero A, Ettorre G, Cillo U, Geller D, Cherqui D, Serrano P, Ferrone C, Aldrighetti L, Kingham T, Mazzaferro V. Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome. JHEP Reports 2024, 6: 101075. PMID: 38961853, PMCID: PMC11220535, DOI: 10.1016/j.jhepr.2024.101075.Peer-Reviewed Original ResearchLong-term outcomes of liver resectionRecurrence-free survivalTime of recurrenceCancer-specific survivalTumor-related factorsDevelopment of hepatocellular carcinomaHepatocellular carcinomaMetabolic syndromeLong-term survivalRisk factorsOverall survivalImpact survivalResection of hepatocellular carcinomaOutcomes of liver resectionCurative intent approachPost-recurrence survivalPredictors of recurrenceHazard of recurrenceTreatment of recurrenceRisk of recurrenceTumor-related deathLong-term outcomesDesigning future trialsAssociated with deathMedian OSThe effect of improved metabolic syndrome parameters on live birth
Spitzer T, Diamond M, Wild R, Legro R, Zhang H, Sun F, Ling S, Santoro N. The effect of improved metabolic syndrome parameters on live birth. Fertility And Sterility 2024, 122: 373-375. PMID: 38641159, DOI: 10.1016/j.fertnstert.2024.04.020.Peer-Reviewed Original ResearchMetabolic syndrome Z-scoreLifestyle interventionLive birthsLive birth rateMetabolic syndrome parametersZ-scoreMetabolic syndromeUnexplained infertilityIntrauterine inseminationOvarian stimulationSyndrome parametersMetabolic parametersObese WomenBirth outcomesLive birth outcomesIntervention phaseImprove metabolic syndromeSecondary analysisFisher's exact testStudy participantsZ-score differenceLifestyle modificationStudent's t-testBirth rateLogistic regressionHypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2)
Habeshian T, Peeri N, De Vivo I, Schouten L, Shu X, Cote M, Bertrand K, Chen Y, Clarke M, Clendenen T, Cook L, Costas L, Dal Maso L, Freudenheim J, Friedenreich C, Gallagher G, Gierach G, Goodman M, Jordan S, La Vecchia C, Lacey J, Levi F, Liao L, Lipworth L, Lu L, Matias-Guiu X, Moysich K, Mutter G, Na R, Naduparambil J, Negri E, O'Connell K, O'Mara T, Hernández I, Palmer J, Parazzini F, Patel A, Penney K, Prizment A, Ricceri F, Risch H, Sacerdote C, Sandin S, Stolzenberg-Solomon R, van den Brandt P, Webb P, Wentzensen N, Wijayabahu A, Wilkens L, Xu W, Yu H, Zeleniuch-Jacquotte A, Zheng W, Du M, Setiawan V. Hypertension and risk of endometrial cancer: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Epidemiology Biomarkers & Prevention 2024, 33: 788-795. PMID: 38530242, PMCID: PMC11145161, DOI: 10.1158/1055-9965.epi-23-1444.Peer-Reviewed Original ResearchConceptsEpidemiology of Endometrial Cancer ConsortiumRisk of endometrial cancerComponents of metabolic syndromeCancer ConsortiumRisk factorsAssociated with endometrial cancer riskIncidence rates of endometrial cancerMultivariable unconditional logistic regression modelStronger magnitude of associationEtiology of endometrial cancerStudy designUnconditional logistic regression modelsIncreased risk of endometrial cancerEndometrial cancer riskRates of endometrial cancerUsers of postmenopausal hormone therapyConfidence intervalsRising prevalence of obesityPrevalence of obesityEndometrial cancerMagnitude of associationEndometrial cancer casesMetabolic syndromeBody mass indexLogistic regression modelsPrediction of metabolic syndrome following a first pregnancy
Kawakita T, Greenland P, Pemberton V, Grobman W, Silver R, Bairey Merz C, McNeil R, Haas D, Reddy U, Simhan H, Saade G. Prediction of metabolic syndrome following a first pregnancy. American Journal Of Obstetrics And Gynecology 2024, 231: 649.e1-649.e19. PMID: 38527600, PMCID: PMC11424779, DOI: 10.1016/j.ajog.2024.03.031.Peer-Reviewed Original ResearchDevelopment of metabolic syndromeArea under the receiver operating characteristic curveMetabolic syndromeNational Cholesterol Education Program Adult Treatment Panel III criteriaAdult Treatment Panel III criteriaPrevalence of metabolic syndromePrediction of metabolic syndromeProspective cohort studyIn-personSecondary analysisCohort studyIII criteriaInclusion criteriaPregnant individualsPrimary outcomeReceiver operating characteristic curveVisit 2Regression modelsPregnancySyndromeDeliveryUnited StatesCharacteristic curveLASSO regression modelYearsAMPlifying metabolic screening for inpatients on antipsychotic medications with a nurse-driven protocol
DeMarco J, Iennaco J. AMPlifying metabolic screening for inpatients on antipsychotic medications with a nurse-driven protocol. Archives Of Psychiatric Nursing 2024, 49: 113-117. PMID: 38734446, DOI: 10.1016/j.apnu.2024.02.007.Peer-Reviewed Original ResearchNurse-driven protocolPsychiatric inpatient settingsInpatient psychiatric unitNursing staffMetabolic screeningPre-interventionInpatient settingPost-implementationSmoking cessationSurveys pre-Psychiatric unitNursesAntipsychotic medicationLipid panelMetabolic syndromeNegative perceptionsScreeningMedicationEmpowermentPatientsPerceptionStaffAntipsychoticsInpatientsUnitsCorrelates of axonal content in healthy adult span: Age, sex, myelin, and metabolic health
Burzynska A, Anderson C, Arciniegas D, Calhoun V, Choi I, Mendez Colmenares A, Kramer A, Li K, Lee J, Lee P, Thomas M. Correlates of axonal content in healthy adult span: Age, sex, myelin, and metabolic health. Cerebral Circulation - Cognition And Behavior 2024, 6: 100203. PMID: 38292016, PMCID: PMC10827486, DOI: 10.1016/j.cccb.2024.100203.Peer-Reviewed Original ResearchNeurologically healthy adultsHealthy adultsLow metabolic riskAdult spanNeural targetsSex differencesIntracranial volumeModifiable health risk factorsMetabolic riskMyelin contentHealth risk factorsAlzheimer's diseaseWhite matterNeurite orientation dispersionPeripheral metabolismMRI approachModifiable factorsAdiposity scoreAdultsMetabolic healthRisk factorsMetabolic syndromeVulnerabilityNeurologyWM
2023
A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design
Davidy T, Yore I, Cukierman-Yaffe T, Ravona-Springer R, Livny A, Lesman-Segev O, Azuri Y, Carmichael O, Kapogiannis D, Zetterberg H, Lin H, Sano M, Beeri M. A feasibility study of the combination of intranasal insulin with oral semaglutide for cognition in older adults with metabolic syndrome at high dementia risk- Study rationale and design. Mechanisms Of Ageing And Development 2023, 218: 111898. PMID: 38159613, DOI: 10.1016/j.mad.2023.111898.Peer-Reviewed Original ResearchConceptsMild cognitive impairmentIntranasal insulinCognitive benefitsCerebrovascular diseaseMetabolic syndromeIntent-to-treat sampleEfficacy of combination therapyPlacebo-controlled feasibility trialGLP-1 receptor agonistsOlder adultsCerebral glucose utilizationAdults aged >Cerebral blood flowNeurobiological markersOral semaglutideCombination therapyReceptor agonistsGlobal cognitionImprove cognitionSafety profileOlder adults aged >White matter hyperintensitiesSemaglutideCognitive impairmentGLP-1The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
Fabris L, Campello E, Cadamuro M, Simioni P. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit. Biochimica Et Biophysica Acta (BBA) - Molecular Basis Of Disease 2023, 1870: 166763. PMID: 37951510, DOI: 10.1016/j.bbadis.2023.166763.Peer-Reviewed Original ResearchMetabolic dysfunction-associated fatty liver diseaseFatty liver diseaseCardiovascular diseaseLiver diseaseInsulin resistanceLiver fibrosisMajor public health problemPublic health problemMAFLD patientsMAFLD progressionCardiometabolic riskMetabolic syndromeOverall mortalityHepatic repairHepatic fibrogenesisHepatic componentGeneral populationTherapeutic targetingHealth problemsTranslational potentialFibrosisDiseaseGenetic factorsRisk profilingStrongest predictorHigh prevalence of low high‐density lipoprotein cholesterol and insulin resistance among children and adolescents living with HIV in Uganda: harbinger for metabolic syndrome?
Kisitu G, Shabanova V, Naiga F, Nakagwa M, Kekitiinwa A, Elyanu P, Paintsil E. High prevalence of low high‐density lipoprotein cholesterol and insulin resistance among children and adolescents living with HIV in Uganda: harbinger for metabolic syndrome? HIV Medicine 2023, 25: 262-275. PMID: 37879630, DOI: 10.1111/hiv.13570.Peer-Reviewed Original ResearchInternational Diabetes FederationLow high-density lipoprotein cholesterolHigh-density lipoprotein cholesterolPrevalence of MetSInsulin resistanceLipoprotein cholesterolMetabolic syndromeAdult Treatment Panel criteriaHomeostatic model assessment indexCross-sectional pilot studyFrequency of MetSModel assessment indexHOMA-IR indexOlder age groupsAge-dependent prevalenceAssociated health problemsATPIII criteriaCentral obesityBlood pressureDiabetes FederationPrimary outcomeClinical centersLifetime riskPanel criteriaHigh prevalenceA Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Ndumele C, Neeland I, Tuttle K, Chow S, Mathew R, Khan S, Coresh J, Baker-Smith C, Carnethon M, Després J, Ho J, Joseph J, Kernan W, Khera A, Kosiborod M, Lekavich C, Lewis E, Lo K, Ozkan B, Palaniappan L, Patel S, Pencina M, Powell-Wiley T, Sperling L, Virani S, Wright J, Singh R, Elkind M, Rangaswami J, Association O. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. Circulation 2023, 148: 1636-1664. PMID: 37807920, DOI: 10.1161/cir.0000000000001186.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseMetabolic risk factorsMetabolic syndromeRisk factorsKidney diseaseCardiovascular diseaseSocial determinantsEarly life preventionUnique management considerationsManagement of patientsInterdisciplinary care modelAmerican Heart AssociationBiological risk factorsScientific statementKidney outcomesLifestyle modificationHeart AssociationClinical managementCare modelClinical careSyndromeClinical phenotypeDiseaseMajor guidelinesWeight loss
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply